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The dosing of anti-Parkinson drugs is considered as the optimal control 
of the symptoms of PD, and increasing the dose of drugs is a common 
method to treat the aggravate state of PD. However, this is a case of PD 
elderly patient who had nephritic syndrome, with an increase in the dose, 
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1. Introduction
This is a case of Parkinson disease occurred in a 
80-year-old male who had nephritic syndrome. With an 
increase in the dose of anti-Parkinson drugs (Madopar® 
3/4 tablet, four times per day; SinemetCR® 1/2 tablet, 
one time per night; Entacapone 1/2 tablet, four times per 
day) due to the degression in efficacy, “Dopamine recep-
tor excitement”—wheezing symptoms happened, which 
was relieved by the down-regulation in the dose of rele-
vant drugs (Madopar® 3/4tablet, three times per day; DC 
SinemetCR® and Entacapone) to confirm the speculation 
of overdose. It reminds us that the seniors with PD is more 
sensitive to anti-Parkinson drugs on the basis of chronic 
kidney disease, and the highly personalized medications 
(such as Madopar®) are needed to relieve the relevant 
symptoms on their renal function.
2. Case Report
A 80-year-old male with 6-year history of Parkinson's 
disease, the patient had previously received Madopar® 
therapy, but he experienced wearing-off time over. Based 
on both the physician's and the patient' s assessment, the 
treatment was switched to 3/4 Madopar® ( levodopa/
benserazide 200/50 mg ) tablet four times per day, 1/2 
Sinemet CR® (CR-carbidopa/ levodopa 50/200 mg) tablet 
one time per night, and entacapone 100 mg four times per 
day, with the aim of improving the curative effect. How-
ever, the patient has suffered from wheezing at rest for the 
last two years, the wheezing occurred 3 times a day, and 
each lasted for 30-60 minutes. No one knew why did the 
phenomenon happen so often? The omnibus symptoms 
20
Journal of Geriatric Medicine | Volume 03 | Issue 01 | April 2021
Distributed under creative commons license 4.0
consisted of wheezing, high blood pressure, elevated heart 
rate, sweating with facies dolorasa, but he knew what was 
happening the whole time.
Meanwhile, the patient has suffered from nephritic 
syndrome, a recent test of renal function showed that the 
creatinine clearance rate decreased (70.8 ml /min), and 
the urine microalbumin increased (79.4mg/L). Elevated 
urine β2 microglobulin (1571μg/L), suggesting poor renal 
function. The other examinations showed that coronary 
CTA and UCG were generally normal. Therefore, it was 
considered that the excretion of the drugs he took before 
was remarkably reduced, leading to the accumulation of 
the anti-Parkinson drugs in his brain, so this dose causes 
the omnibus symptoms mentioned above. As a result, 
the doctor in charge gradually reduced the patient's an-
ti-Parkinson medication to only 3/4 Madopar® tablet 
three times per day, and the omnibus symptoms described 
previously (wheezing, high blood pressure, elevated heart 
rate, sweating) were subsequently relieved.
3. Discussion
Generally speaking, the efficacy of anti-Parkinson 
drugs on a Parkinson individual, such as Madopar®, 
would wear off with the progress of Parkinson disease, 
and the agreement between physicians and patients might 
be easily reached to compensate the “loss”, by means 
of increasing one-single dose or adding other kinds of 
anti-Parkinson drugs to it, to restore the previous effec-
tiveness. Being worth mentioning, the renal function in-
volving drug excretion in senile patients with Parkinson 
disease is also declined stepwise over the course due to 
aging [1]. In this case, the intention of elevation in dose to 
cover the “gap” somehow evolved into “overaction” of 
anti-Parkinson drugs in his brain, as a result, the omnibus 
symptoms of Dopamine-Receptor excitement (wheezing 
symptoms) occurred. The speculation mentioned above 
was confirmed by down-regulating the daily dose of rel-
evant drugs (such as Madopar®) to relieve the wheezing 
symptoms, suggesting that we should pay more attention 
to this phenomenon of overdose from anti-Parkinson 
drugs in a senile PD patient with renal insufficiency. 
Levodopa-induced dyskinesias (LID) are abnormal invol-
untary movements that develop progressively with repeat-
ed dopamine replacement therapy in Parkinson’s disease [2]. 
The pathophysiology of LID comprises many functional-
ly-related abnormalities in neurotransmission which lead 
to abnormalities in the rate, pattern of breathing abnor-
mality within and outside the basal ganglia [3]. Restrictive 
breathing abnormalities have been reported in 28% to 
94% of people living with Parkinson’s disease. The under-
lying mechanisms of this pattern of breathing abnormality 
in PD are not fully understood so far [4], which kept asking 
us to remember that the correlation between the patient's 
own personal condition and the appropriate amount of the 
drug couldn't be ignored.
4. Conclusions
Our speculation mentioned above was a bit different 
from those reviewed here, that is, the seniors with PD is 
more sensitive to anti-Parkinson drugs on the basis of re-
nal degeneration and the highly personalized medications 
(such as Madopar®) are needed to relieve the relevant 
symptoms on their renal function; suggesting that geri-
atrician should pay more attention to the overaction of 
anti-Parkinson drugs in a senile PD patient with renal in-
sufficiency.
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